Descartes-08 in Dermatomyositis: NCT07089121 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1/2
Clinical phase
Recruiting
Recruitment status
50
Planned enrollment
2027-12-01
Primary-completion proxy
Executive view
NCT07089121 evaluates Descartes-08 in Dermatomyositis. The disclosed sponsor is Cartesian Therapeutics, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2, assessed over Days 22 and 50 for Part1 , Days 22, 50 and Months 3,6,9 and 12 for part 2.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07089121 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Dermatomyositis landscape. Drug & Asset MCP drug_fetch was queried for Descartes-08, while Company & Deal Intelligence MCP organization_fetch was queried for Cartesian Therapeutics, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07089121 | Descartes-08 | Phase 1/2 / Recruiting | Cartesian Therapeutics, Inc. | United States | Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2 Days 22 and 50 for Part1 , Days 22, 50 and Months 3,6,9 and 12 for pa… | 2027-12-01 |
| NCT07583030 | LVIVO-TaVec400 | Early Phase 1 / Not yet recruiting | Sponsor not reported | China | The incidence of Dose-limiting toxicity (DLT) 28 days after LVIVO-TaVec400 infusion (Day 1) | 2028-09-20 |
| NCT07556120 | HN-2301 | Phase 1 / Not yet recruiting | Shenzhen Hongxin Biotechnology Co., Ltd. | China | Incidence of treatment-emergent adverse events (TEAEs) Up to 3 months | 2027-05-31 |
| NCT07526493 | Fludarabine Phosphate | Phase 1 / Recruiting | Huazhong University of Science Tongji Hospital, Tongji Medical College | China | Incidence of Dose-Limiting Toxicities (DLTs) First infusion date of QH103 up to 28 days | 2027-12-31 |
| NCT07499323 | Talquetamab | Not Applicable / Not yet recruiting | Chongqing Medical University /The First Affiliated Hospital/ | Geography not reported | MG-ADL score baseline, and 1-6 months | 2027-03-20 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07089121 is a Phase 1/2, recruiting study with 50 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2” over “Days 22 and 50 for Part1 , Days 22, 50 and Months 3,6,9 and 12 for part 2.” The retrieved endpoint description is: The primary endpoint for Part-1 is the Maximum Tolerated Dose (MTD), defined as the Dose Level at which no more than 20% of the patients treated have shown Dose-Limiting Toxicity (DLT), i.e. at which 3 patients received all 6 weekly infusions without a DLT by Day 50; or 6 patients received 3 weekly infusions with no more than 1 patient having a DLT by Day 50. The primary endpoint for Part-2 is the type and frequency of treatment-related SAEs. This will be assessed on Days 22, 50 and Months 3,6,9,12.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 50 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Dermatomyositis. These records do not establish direct evidence for NCT07089121 unless the registration number matches.
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…
Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552
Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331
Investigating intravenous efgartigimod in juvenile generalized myasthenia gravis: Results from the ADAPT JR study
Phase 2/3; n=11; MSE(Cycle 1) = 72.7 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Descartes-08.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Cartesian Therapeutics, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Descartes-08 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07089121
Protocol source: https://clinicaltrials.gov/study/NCT07089121
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Descartes-08 in Dermatomyositis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2 and 2027-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
